FGFR fusion

#EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR fusion-positive advanced #cholangiocarcinoma https://t.co/jBV3Ozice5 #fondazionebonadonna #cancerresearch #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)

Cool! We see FGFR fusions in glioma, wonder if a similar immune response is seen there (@shawnkothari)

What type of ctDNA assays do you like to use here? Is there a Signatera-like/tissue-informed choice in #urothelialcarcinoma, or just a general cell-free DNA approach? #TumorBoardTuesday I imagine this could also be really interesting when treating FGFR fusions w targeted agents. (@JohnEbbenMDPhD)

YOUNG 2 YOUNG APPROFONDIMENTO TEMATICO | L'opinione dell'esperto Fight against cholangiocarcinoma. Le fusioni di FGFR A cura di Alessandro Pastorino, @Marzia_DelRe @matteo_fassan @Mom_enji https://t.co/IItX2kE6t6 #oncology #YoungtoYoung #cancer #cholangiocarcinoma #FGFR (@ACCMEDorg)

#TumorBoardTuesday ~50% - wow😲 🤔Are there data on the kinds of alterations? ➡️In #cholangiocarcinoma, for example, only FGFR-fusions respond to FGFR⛔️ (@MPishvaian)

Glad to be part of this meeting faculty with a talk about #FGFR gene fusion as a #target for novel #treatments especially for #cholangiocarcinoma #CCA @NicolaNormanno @AIOMtweet @HUNIMED @HumanitasMilano (@LorenzaRimassa)

IKF is happy to announce that the ADVACE study has recruited its first patient. The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments (@salahAlBatran)

@DSolit @sloan_kettering discusses Why we need #NGS in patients with #bladdercancer? Look for FGFR mutations/fusions, germline testing, assist with tumor subtypes, platinum sensitivity biomarkers, etc) #GU22 @ASCO @OncoAlert @BladderCancerUS (@apolo_andrea)

➡️ORR ✅FGFR fusions =25.0% ✅FGFR mutations =23.1% ✅partial responses in ➡️cholangiocarcinoma, head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, & non-small cell lung cancer @OncoAlert (@VivekSubbiah)

Pemigatinib was associated with clinical activity across tumors driven by FGFR fusions+mutations. These results prompted a registrational study in cholangiocarcinoma & phase II/III trials in many tumor types demonstrating the benefit of #PrecisionMedicine in early phase trials. (@VivekSubbiah)

👆🏾next level of #precisionmedicine #precisiononcology 📈#FGFR ⬆️#DNARepair #Cholangiocarcinoma Selecting the right biology. With more targeted therapy options, the recurrences too are treatable. ~ 30% of transplanted had the FGFR-fusions. IDH mutually exclusive. @OncoAlert (@pashtoonkasi)

Another☝🏽intriguing observation: CA 19-9 helpful when elevated. But can be deceiving. We have noted this as well, and others group have published this too: #FGFR🧬 fusion #intrahepatic cholangiocarcinoma tends to NOT produce 19-9. One way to prescreen. https://t.co/QCwfyh0ZDg (@pashtoonkasi)

@MiteshBorad providing an overview on the standand of care for CCA and next challengues at #ccasummit21 🧬targeted therapy already a reallity: FGFR-fusions & IDH1 mut 👌Next targeted therapies ahead 👉Need to go from bedside to bench & vice versa #livercancerawarenessmonth (@JesusMBanales)

Today’s molecular MDT - welcoming colleagues from nepal bangladesh kenya! Molecular drivers for HCC - wonderful talk @GABOUALFA 🙏🏽FGFR fusions, PIK3CA mut in Cholangiocarcinoma- lot to learn still. chemo remains SOC. @ApolloProton @HospitalsApollo @dmukherji @curecc @sujithonco (@SirohiBhawna)

I thought the same @DrBonillaOnc. With many FGFR⛔️ & 2 now approved for #cholangiocarcinoma, “indigestion” be for FGFR🧬fusions. I didn’t realize it was an autocorrect for infigratinib. Sounds cool! 💡Of note📝 resistance mechanisms may be drug 🆚 class specific. Timely #ASCO21 https://t.co/nNekTuDbJN (@pashtoonkasi)

intrahepatic cholangio bone liver peritoneum progressed on first line chemo after 6 months, FGFR-TACC1 fusion,BAP 1,MSS,TMB low, started pemigatanib PD after 3 months. any role of alternative FGFR inhibitor? @GIcancerDoc @rachnatshroff #hpbcsm (@antonyruggeri)

MT @agrothey [Sep 27, 2019] Pemigatinib in intrahepatic cholangio ca with FGFR fusions/ rearrangements. #ESMO19 https://t.co/kDiSsA3ls0 #PrecisionMedicine #hpbcsm (@mtmdphd)

We picked up more #FGFR fusions on #ctDNA🩸🧬. Not that tissue didn’t pick them up. But tissue NGS especially in the context of diseases like #cholangiocarcinoma where often it’s not sufficient can be an issue. Tissue is still good standard; liquid complements. #TumorBoardTuesday https://t.co/1vKcqiTium (@pashtoonkasi)

#TumorBoardTuesday Interesting.....a couple months ago @pashtoonkasi reminded us that NTRK fusions are MORE common in MSI-high #ColorectalCancer Do we know the association between FGFR fusions and MSS in #stomachcancer ❓ @DocCatenacci @rachnatshroff @JavleMilind (@MPishvaian)

Yes. ✅ the ongoing FIGHT-207 study actually allow for primary brain tumors with #FGFR 🧬 fusion. We are/have enrolled patients into this trial. Pemigatinib. https://t.co/KBEtiORlsF (@pashtoonkasi)

#TumorBoardTuesday Did someone say #ctDNA & #cholangiocarcinoma - see this #Tweetorial🧵 on #LiquidBiopsies #CirculatingTumorDNA #ctDNA in a very 🎯 “Target-rich” disease #HPBCSM ~3️⃣0️⃣% actionable findings We found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. ?bias (@pashtoonkasi)

Tune in to #TumorBoardTuesday this Tuesday, February 23rd at 6 pm MST with @rachnatshroff. She will present a case of #cholangiocarcinoma with: An FGFR fusion AND an IDH2 mutation (@curecc)

#GI21 on post-FGFR⛔️resistance. Please do 👀/🖍 💭 on my📝on #FGFR-fusion➕ #cholangiocarcinoma. 🆓 Available now👉🏾 https://t.co/W3lMsiJLuT Acquired 📈🔴🟠⚪️ #FGFR mutations ➡️ FGFR⛔️ #ctDNA 🩸🧬;📉chemo💡♻️. HETEROGENEITY: 1️⃣Intra-tumoral 2️⃣Temporal ⏳ #HPBCSM #LiquidBiopsies (@pashtoonkasi)

Infigratinib, an FGFR1-3 ⛔️ shows activity in IHCC with FGFR fusion/rearrangement in the BGJ386 as presented by @MJavle #GI21 (@DrEstfan)

🧵3️⃣ #GI21 We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding. Interestingly we found #FGFR🧬fusions 🩸LIQUID>>TISSUE🔬 💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert (@pashtoonkasi)

🧵4️⃣ #GI21 Focusing #FGFR 🧬 fusions & fusions in general, you have to know your testing platform. Whether it’s tissue🔬or🩸liquid, fusions can be detected. 🩸is not meant to replace🔬but for some pts may be the only option. Tissue often not sufficient in #cholangiocarcinoma. (@pashtoonkasi)

#GI21 time for another #Tweetorial🧵 on #LiquidBiopsies #CirculatingTumorDNA #ctDNA in a very 🎯 “Target-rich” disease #Cholangiocarcinoma #HPBCSM ~3️⃣0️⃣% actionable findings Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert @TempusLabs (@pashtoonkasi)